Acadia's Alzheimer's drug narrowly misses Phase 2 primary endpoint

September 24, 2026 7:00 AM

Acadia Pharmaceuticals (Nasdaq: ACAD) reported topline results from the Phase 2 portion of its RADIANT clinical trial evaluating remlifanserin for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found